[go: up one dir, main page]

NO20054311D0 - HIV-repliksjonsinhiberende pyrimidiner og triaziner - Google Patents

HIV-repliksjonsinhiberende pyrimidiner og triaziner

Info

Publication number
NO20054311D0
NO20054311D0 NO20054311A NO20054311A NO20054311D0 NO 20054311 D0 NO20054311 D0 NO 20054311D0 NO 20054311 A NO20054311 A NO 20054311A NO 20054311 A NO20054311 A NO 20054311A NO 20054311 D0 NO20054311 D0 NO 20054311D0
Authority
NO
Norway
Prior art keywords
triazines
hiv replication
replication inhibitory
pyrimidines
inhibitory pyrimidines
Prior art date
Application number
NO20054311A
Other languages
English (en)
Other versions
NO20054311L (no
Inventor
Jan Heeres
Kurt Hertogs
Marc Rene De Jonge
Lucien Maria Henricus Koymans
Eva Bettens
Jerome Emile George Guillemont
Elisabeth Therese Jea Pasquier
Paulus Joannes Lewi
Frederik Frans Desire Daeyaert
Hendrik Maarten Vinkers
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20054311D0 publication Critical patent/NO20054311D0/no
Publication of NO20054311L publication Critical patent/NO20054311L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20054311A 2003-02-20 2005-09-19 HIV-repliksjonsinhiberende pyrimidiner og triaziner NO20054311L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
PCT/EP2004/050175 WO2004074261A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (2)

Publication Number Publication Date
NO20054311D0 true NO20054311D0 (no) 2005-09-19
NO20054311L NO20054311L (no) 2005-10-27

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20054311A NO20054311L (no) 2003-02-20 2005-09-19 HIV-repliksjonsinhiberende pyrimidiner og triaziner
NO20054312A NO20054312L (no) 2003-02-20 2005-09-19 HIV-replikasjonsinhiberende pyrimidiner og triaziner

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20054312A NO20054312L (no) 2003-02-20 2005-09-19 HIV-replikasjonsinhiberende pyrimidiner og triaziner

Country Status (27)

Country Link
US (2) US7442705B2 (no)
EP (2) EP1603887B1 (no)
JP (2) JP4586013B2 (no)
KR (2) KR20050099994A (no)
CN (2) CN1751031B (no)
AP (1) AP2005003373A0 (no)
AR (2) AR044500A1 (no)
AT (2) ATE506353T1 (no)
AU (2) AU2004213187B2 (no)
BR (2) BRPI0407741B8 (no)
CA (2) CA2516699C (no)
CL (2) CL2004000303A1 (no)
CY (1) CY1106788T1 (no)
DE (2) DE602004006383T2 (no)
DK (1) DK1597238T3 (no)
EA (2) EA011256B1 (no)
ES (1) ES2287734T3 (no)
HR (2) HRP20050821A2 (no)
IL (2) IL169596A (no)
MX (2) MXPA05008866A (no)
MY (1) MY138308A (no)
NO (2) NO20054311L (no)
NZ (2) NZ541601A (no)
PL (2) PL227295B1 (no)
PT (1) PT1597238E (no)
TW (2) TW200500346A (no)
WO (2) WO2004074262A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2567574C (en) 2004-04-08 2013-01-08 Targegen, Inc. Benzotriazine inhibitors of kinases
RU2468021C2 (ru) 2004-08-25 2012-11-27 Таргеджен, Инк. Гетероциклические соединения и их применение
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
AU2006309013B2 (en) 2005-11-01 2012-06-28 Impact Biomedicines, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ, インコーポレイテッド Jak経路の阻害のための組成物および方法
ES2618057T3 (es) * 2006-12-29 2017-06-20 Janssen Sciences Ireland Uc Pirimidinas 5,6-sustituidas inhibidoras del VIH
BRPI0720858B8 (pt) * 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
BRPI0908637B8 (pt) 2008-05-21 2021-05-25 Ariad Pharma Inc composto e composição farmacêutica do mesmo
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2344458A1 (en) 2008-09-11 2011-07-20 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2018019204A1 (zh) * 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
JP7593947B2 (ja) 2019-05-10 2024-12-03 デシフェラ・ファーマシューティカルズ,エルエルシー フェニルアミノピリミジンアミドオートファジー阻害剤およびその使用方法
LT3966206T (lt) 2019-05-10 2023-11-10 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidino amido autofagijos inhibitoriai ir jų naudojimo būdai
EP3983081A1 (en) 2019-06-17 2022-04-20 Deciphera Pharmaceuticals, LLC Aminopyrimidine amide autophagy inhibitors and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EE04850B1 (et) * 1998-03-27 2007-06-15 Janssen Pharmaceutica N.V. Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
KR100658489B1 (ko) * 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Hiv 복제를 억제하는 피리미딘
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
CA2386218A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
AU2002216650A1 (en) * 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1479397B1 (en) * 2002-02-05 2011-06-08 Astellas Pharma Inc. 2,4,6-triamino-1,3,5-triazine derivative
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
CN1665789A (zh) * 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
JP2006514989A (ja) * 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
NO20054311L (no) 2005-10-27
IL169647A0 (en) 2007-07-04
CA2516589C (en) 2012-04-17
EP1603887B1 (en) 2011-04-20
PT1597238E (pt) 2007-08-08
US7585870B2 (en) 2009-09-08
US20060142571A1 (en) 2006-06-29
CN1751031B (zh) 2010-07-21
WO2004074261A1 (en) 2004-09-02
EA011256B1 (ru) 2009-02-27
BRPI0407741A (pt) 2006-02-14
US20060194804A1 (en) 2006-08-31
EA200501327A1 (ru) 2006-02-24
ATE361915T1 (de) 2007-06-15
KR20050094896A (ko) 2005-09-28
IL169596A (en) 2017-02-28
CY1106788T1 (el) 2012-05-23
BRPI0407741B1 (pt) 2018-05-29
CA2516589A1 (en) 2004-09-02
KR20050099994A (ko) 2005-10-17
CL2004000306A1 (es) 2005-04-08
US7442705B2 (en) 2008-10-28
CL2004000303A1 (es) 2005-04-08
ES2287734T3 (es) 2007-12-16
CA2516699C (en) 2011-07-12
CA2516699A1 (en) 2004-09-02
PL227295B1 (pl) 2017-11-30
IL169596A0 (en) 2007-07-04
EP1597238B1 (en) 2007-05-09
CN1751031A (zh) 2006-03-22
NZ542428A (en) 2007-11-30
TW200510339A (en) 2005-03-16
PL378136A1 (pl) 2006-03-06
BRPI0407732A (pt) 2006-02-14
EP1603887A1 (en) 2005-12-14
TW200500346A (en) 2005-01-01
JP2006518356A (ja) 2006-08-10
WO2004074262A1 (en) 2004-09-02
MXPA05008867A (es) 2005-10-05
DE602004006383T2 (de) 2008-01-10
EA200501326A1 (ru) 2006-02-24
HRP20050820A2 (en) 2006-11-30
IL169647A (en) 2013-05-30
DE602004032321D1 (de) 2011-06-01
EP1597238A1 (en) 2005-11-23
PL378064A1 (pl) 2006-02-20
AU2004213187A1 (en) 2004-09-02
DK1597238T3 (da) 2007-09-10
AP2005003373A0 (en) 2005-09-30
NO20054312L (no) 2005-11-16
HRP20050821A2 (en) 2006-11-30
JP4586014B2 (ja) 2010-11-24
CN100572364C (zh) 2009-12-23
NO20054312D0 (no) 2005-09-19
JP2006518357A (ja) 2006-08-10
BRPI0407741B8 (pt) 2021-05-25
AR044500A1 (es) 2005-09-14
NZ541601A (en) 2007-09-28
AU2004213186A1 (en) 2004-09-02
AU2004213187B2 (en) 2009-11-05
PL226954B1 (pl) 2017-10-31
MXPA05008866A (es) 2005-10-05
AR044499A1 (es) 2005-09-14
JP4586013B2 (ja) 2010-11-24
EA010423B1 (ru) 2008-08-29
AU2004213186B2 (en) 2009-10-01
CN1751030A (zh) 2006-03-22
DE602004006383D1 (de) 2007-06-21
MY138308A (en) 2009-05-29
ATE506353T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
NO20054312D0 (no) HIV-replikasjonsinhiberende pyrimidiner og triaziner
DK1483247T3 (da) Arylsubstituerede pyrimidiner og anvendelsen deraf
DK1527067T3 (da) 4-Trifluormethylpyrazolylsubstituerede pyridiner og pyrimidiner
NO20024308D0 (no) Arylsubstituerte pyridiner, pyrimidiner og triaziner og deres anvendelse
ATE472536T1 (de) Pyridin- und pyrimidin-derivate
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
IS3007B (is) Ónæmisbælandi efnasambönd og efnablöndur
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
NL1024643A1 (nl) Purineverbindingen en gebruik daarvan.
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK1642499T3 (da) Fungicidblandinger på basis af prothioconazol og picozystrobin
ATE500254T1 (de) Die replikation von hiv hemmende purinderivate
NO20011696D0 (no) Hiv-replikasjonsinhiberende pyrimidiner
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
NO20044032L (no) Indolamidderivater med glykogenfosforylase inhibitorisk aktivitet
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
ATE366242T1 (de) 5-substituierte chinazolinonderivate
DK1651607T3 (da) 6-(1,1-difluoralkyl)-4-aminopicolinater og deres anvendelse som herbicider
FR2833630B1 (fr) Glissiere de securite bois
DK1680405T3 (da) Bengamidderivater og deres anvendelse til behandling af kræftsygdomme
ZA200506622B (en) HIV replication inhibiting pyrimidines and triazines
DK1781631T3 (da) Diarylmethylpiperazinderivater, præparater dermed og anvendelser deraf
TWI315199B (en) Hiv replication inhibiting pyrimidines

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application